Oral IgY-Colostrum Composition for Animal Enteric Infections
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for diarrhea and enteric infections in animals, particularly dogs and cats, are inadequate, costly, and lack effective, broad-spectrum solutions, with high mortality rates for conditions like canine parvovirus.
Innovation Solution
A composition combining avian-sourced IgY antibodies, specific to multiple diarrhea-causing pathogens, embedded in a protective protein matrix, such as bovine colostrum, to provide passive immunity and protect against gastrointestinal destruction.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If maternal colostrum is used to provide passive immunity to neonates, then immunity transfer is achieved, but the level of antibody transfer is insufficient for certain pathogens when maternal exposure is recent
Solution Approach 1:
The patent uses avian antibodies (IgY from egg yolk) as an intermediary substance to bridge the gap between maternal immunity and neonatal needs. These avian antibodies are administered to the neonate alongside or instead of maternal colostrum, providing additional antibody coverage particularly for pathogens the mother may not have been exposed to recently. The avian antibodies act as a mediator that supplements the insufficient maternal antibody transfer.
2Reliability
If avian antibodies are orally delivered to treat gastrointestinal infections, then passive immunity is provided, but effectiveness is diminished by stomach acid and digestion enzymes
Solution Approach 1:
The patent employs bovine colostrum as a protective intermediary matrix that shields the avian antibodies from gastric acid and digestion enzymes. The colostrum forms a protective environment in the gastrointestinal tract that allows the avian antibodies to survive and remain functional. This intermediary protection enables the antibodies to reach their target pathogens without being destroyed by the harsh gastric environment.
Solution Approach 2:
The invention creates a composite therapeutic formulation combining avian antibodies with bovine colostrum. This composite material leverages the protective properties of colostrum (which contains protective proteins and a favorable pH environment) to preserve the activity of the avian antibodies. The composite structure allows both components to work synergistically, with colostrum protecting antibodies while antibodies provide pathogen neutralization.
3Ease of operation
If standard treatments for canine parvovirus are used, then supportive care is provided, but mortality rates remain high and costs are excessive
Solution Approach 1:
The patent introduces avian antibodies as an intermediary therapeutic agent that directly targets and neutralizes parvovirus. These antibodies are administered to puppies alongside supportive care measures, providing active viral neutralization rather than merely managing symptoms. The avian antibodies serve as a mediator between the virus and the immune system, facilitating more effective viral clearance and reducing mortality.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The composition effectively treats and prevents diarrhea and enteric infections by providing broad-spectrum protection against a range of pathogens, reducing morbidity and mortality, and is cost-effective with minimal side effects.
Implementation Method 1
Antibodies bind a portion of the antigen (the antigenic determinant or epitope) with the antigen combining site on the antibody
Implementation Method 2
The antibodies are embedded in a protective protein matrix so as to be reactive with specific pathogens while being protected from destruction by the gastrointestinal environment
Implementation Method 3
colostrum contains lactoferrin, an iron-binding protein that prevents bacteria and viruses from obtaining iron necessary for replication
Implementation Method 4
colostrum is a source of two major growth factors, Transforming Growth Factors (TGF) alpha and beta, as well as a source of Insulin-Growth Factors 1 and 2. These factors promote tissue repair and development
Implementation Method 5
colostrum is also a source of Hepatocyte Growth Factor (HGF, also known as 'scatter factor'), which stimulates the growth and expansion of intestinal wall cells
Data Source
AI summary
The composition may be used therapeutically or prophylactically and is directed toward a cluster of diarrhea-causing pathogens which cause illness or death in animals, including dogs and cats. It is prepared from a powdered egg preparation and powdered protein matrix, such as bovine colostrum. The eggs are collected from hens which have been immunized with the relevant pathogens or toxins. When the matrix includes colostrum, the powdered colostrum is derived from non-hyperimmune cattle. The vaccination strategy includes the use of antibody cross-reactivity between toxins or pathogens which cause diarrhea. For some diseases, including canine parvo, the clinical improvement using this therapeutic exceeds the standard of care. Instead of a pharmaceutical product, this composition is an orally administered food product with the same safety profile as eggs and milk.